OCULAR THERAPEUTIX, INC Revenue Breakdown
No Revenue Breakdown for OCUL on this site yet.
- 2025-12-31: Others Not split by product in the filing$51.95M100.00%; Total revenue $51.95M.
- 2024-12-31: Others Not split by product in the filing$63.72M100.00%; Total revenue $63.72M.
- 2023-12-31: Others Not split by product in the filing$58.44M100.00%; Total revenue $58.44M.
- 2022-12-31: Others Not split by product in the filing$51.49M100.00%; Total revenue $51.49M.
Source checked: the stored Revenue Breakdown page for OCUL.
Revenue by product
Each year (12 month)
| Fiscal year end | Others | Total revenue |
|---|---|---|
| 2025-12-31 | Not split by product in the filing $51.95M 100.00% | $51.95M |
| 2024-12-31 | Not split by product in the filing $63.72M 100.00% | $63.72M |
| 2023-12-31 | Not split by product in the filing $58.44M 100.00% | $58.44M |
| 2022-12-31 | Not split by product in the filing $51.49M 100.00% | $51.49M |
| 2021-12-31 | Not split by product in the filing $43.52M 100.00% | $43.52M |
| 2020-12-31 | Not split by product in the filing $17.40M 100.00% | $17.40M |
| 2019-12-31 | Not split by product in the filing $4.23M 100.00% | $4.23M |
| 2018-12-31 | Not split by product in the filing $1.99M 100.00% | $1.99M |
| 2017-12-31 | Not split by product in the filing $1.92M 100.00% | $1.92M |
| 2016-12-31 | Not split by product in the filing $1.89M 100.00% | $1.89M |
| 2015-12-31 | Not split by product in the filing $1.75M 100.00% | $1.75M |
| 2014-12-31 | Not split by product in the filing $772.00K 100.00% | $772.00K |
| 2012-12-31 | $10.00K |
Each quarter (3 month)
| Quarter end | Products | Others | Total revenue |
|---|---|---|---|
| 2026-06-30 | $13.47M 100.00% | $13.47M | |
| 2026-03-31 | Not split by product $10.79M 100.00% | $10.79M | |
| 2025-12-31 | Not split by product $13.25M 100.00% | $13.25M | |
| 2025-09-30 | Not split by product $14.54M 100.00% | $14.54M | |
| 2025-06-30 | $13.39M 99.52% | Collaboration revenue $64.00K 0.48% | $13.46M |
| 2025-03-31 | Not split by product $10.70M 100.00% | $10.70M | |
| 2024-12-31 | Not split by product $17.08M 100.00% | $17.08M | |
| 2024-09-30 | Not split by product $15.43M 100.00% | $15.43M | |
| 2024-06-30 | Not split by product $16.44M 100.00% | $16.44M | |
| 2024-03-31 | Not split by product $14.77M 100.00% | $14.77M | |
| 2023-12-31 | Not split by product $14.80M 100.00% | $14.80M | |
| 2023-09-30 | Not split by product $15.08M 100.00% | $15.08M | |
| 2023-06-30 | Not split by product $15.19M 100.00% | $15.19M | |
| 2023-03-31 | Not split by product $13.37M 100.00% | $13.37M | |
| 2022-12-31 | Not split by product $14.07M 100.00% | $14.07M | |
| 2022-09-30 | Not split by product $11.96M 100.00% | $11.96M | |
| 2022-06-30 | Not split by product $12.27M 100.00% | $12.27M | |
| 2022-03-31 | Not split by product $13.19M 100.00% | $13.19M | |
| 2021-12-31 | Not split by product $12.31M 100.00% | $12.31M | |
| 2021-09-30 | Not split by product $12.15M 100.00% | $12.15M | |
| 2021-06-30 | Not split by product $11.72M 100.00% | $11.72M | |
| 2021-03-31 | Not split by product $7.34M 100.00% | $7.34M | |
| 2020-12-31 | Not split by product $7.35M 100.00% | $7.35M | |
| 2020-09-30 | Not split by product $5.88M 100.00% | $5.88M | |
| 2020-06-30 | Not split by product $1.57M 100.00% | $1.57M | |
| 2020-03-31 | Not split by product $2.61M 100.00% | $2.61M | |
| 2019-12-31 | Not split by product $2.26M 100.00% | $2.26M | |
| 2019-09-30 | Not split by product $829.00K 100.00% | $829.00K | |
| 2019-06-30 | Not split by product $650.00K 100.00% | $650.00K | |
| 2019-03-31 | Not split by product $492.00K 100.00% | $492.00K | |
| 2018-12-31 | Not split by product $504.00K 100.00% | $504.00K | |
| 2018-09-30 | Not split by product $498.00K 100.00% | $498.00K | |
| 2018-06-30 | Not split by product $648.00K 100.00% | $648.00K | |
| 2018-03-31 | Not split by product $340.00K 100.00% | $340.00K | |
| 2017-12-31 | Not split by product $487.00K 100.00% | $487.00K | |
| 2017-09-30 | Not split by product $523.00K 100.00% | $523.00K | |
| 2017-06-30 | Not split by product $438.00K 100.00% | $438.00K | |
| 2017-03-31 | Not split by product $475.00K 100.00% | $475.00K | |
| 2016-12-31 | Not split by product $511.00K 100.00% | $511.00K | |
| 2016-09-30 | Not split by product $477.00K 100.00% | $477.00K | |
| 2016-06-30 | Not split by product $441.00K 100.00% | $441.00K | |
| 2016-03-31 | Not split by product $458.00K 100.00% | $458.00K | |
| 2015-12-31 | Not split by product $436.00K 100.00% | $436.00K | |
| 2015-09-30 | Not split by product $429.00K 100.00% | $429.00K | |
| 2015-06-30 | Not split by product $459.00K 100.00% | $459.00K | |
| 2015-03-31 | Not split by product $426.00K 100.00% | $426.00K | |
| 2014-12-31 | Not split by product $505.00K 100.00% | $505.00K | |
| 2014-09-30 | Not split by product $143.00K 100.00% | $143.00K | |
| 2014-06-30 | Not split by product $97.00K 100.00% | $97.00K | |
| 2014-03-31 | Not split by product $27.00K 100.00% | $27.00K |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |